Seer, Inc.
HealthcareNASDAQ:SEER · NASDAQ Global Select
+$0.02 today
Vol 0.10M · Avg 0.33M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$15.0M of revenue converted into -$70.5M of net income for the selected period. Gross margin is 47.2% and net margin is -479.4%, showing how much revenue survives after costs and taxes. EPS is $-1.24, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M +15.6% | $13.9M -8.1% | $15.2M +3.4% | $14.7M +129.7% | $6.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $14.2M +99.8% | $7.1M -48.2% | $13.7M -4.0% | $14.3M +111.3% | $6.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.9M -72.2% | $6.8M +371.5% | $1.4M +277.3% | $384.0K +202.7% | -$374.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | 11.8% -37.2pp | 49.0% +39.4pp | 9.5% +6.9pp | 2.6% +8.5pp | -5.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $37.8M -25.3% | $50.6M +6.6% | $47.4M +3.6% | $45.8M +57.3% | $29.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $42.6M -24.7% | $56.6M -4.0% | $59.0M +12.0% | $52.6M +24.7% | $42.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $80.4M -24.9% | $106.9M +0.5% | $106.4M +8.1% | $98.4M +38.0% | $71.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $6.1M -1.2% | $6.2M +10.7% | $5.6M -5.5% | $5.9M +65.6% | $3.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$67.3M +16.2% | -$80.3M +0.5% | -$80.7M +7.3% | -$87.1M -28.8% | -$67.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -417.5% +158.4pp | -575.9% -44.4pp | -531.5% +61.3pp | -592.9% +464.5pp | -1057.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$78.5M +21.6% | -$100.1M +4.6% | -$104.9M -7.0% | -$98.0M -36.7% | -$71.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -486.7% +231.0pp | -717.7% -26.5pp | -691.2% -23.6pp | -667.6% +453.7pp | -1121.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $11.5M -30.9% | $16.7M -6.2% | $17.8M +286.0% | $4.6M +1311.7% | $326.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 -100.0% | $22.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $5.1M -62.9% | $13.6M -27.1% | $18.7M +267.6% | $5.1M +863.4% | $527.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$73.4M +15.1% | -$86.5M -0.3% | -$86.3M +7.2% | -$93.0M -30.6% | -$71.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -455.4% +164.9pp | -620.2% -51.9pp | -568.3% +64.8pp | -633.1% +480.0pp | -1113.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $201.0K +105.1% | $98.0K | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$73.6M +15.0% | -$86.6M -0.4% | -$86.3M +7.2% | -$93.0M -30.6% | -$71.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -456.6% +164.3pp | -620.9% -52.6pp | -568.3% +64.8pp | -633.1% +480.0pp | -1113.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +7.9% | -$1 -3.0% | -$1 +4.9% | -$1 -25.7% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +7.9% | -$1 -3.0% | -$1 +4.9% | -$1 -25.7% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $57.4M -7.9% | $62.3M -2.4% | $63.9M +2.3% | $62.4M +2.6% | $60.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $57.4M -7.9% | $62.3M -2.4% | $63.9M +2.3% | $62.4M +2.6% | $60.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.09B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
$1.19B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$841.97M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$129.89M
PepGen Inc.
NASDAQ:PEPG
$101.68M
MediciNova, Inc.
NASDAQ:MNOV
$60.54M
Generation Bio Co.
GBIO
$35.98M
Anebulo Pharmaceuticals, Inc.
ANEB
$15.91M
HCW Biologics Inc.
HCWB
$2.67M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SEER generate?
Seer, Inc. (SEER) reported $16.12M of revenue in fiscal 2025.
Is SEER profitable?
Seer, Inc. (SEER) reported -$73,600,000.00 of net income, with a net margin of -456.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.